Introduction
============

Diabetes is a serious and chronic disease that can lead to various complications and premature death. According to the "Global Report on Diabetes (2016)" by World Health Organization (WHO), the number of diabetic adults has quadrupled to 422 million since 1980. This recent dramatic rise is largely due to the incidence of type 2 diabetes in low- and middle-income countries (LMIc). In all, 43% of deaths in a total or 3.7 million deaths related to diabetes in 2012 is attributable to higher than optimal blood glucose, and this occurs before the age of 70,[@b1-tcrm-14-1813] which is much shorter than the life expectancy of 81.3 mean years among the Organisation for Economic Co-operation and Development (OECD) countries in 2015.[@b2-tcrm-14-1813] Since diabetes is a chronic lifelong condition, adherence to medications and self-monitoring of blood glucose are quite challenging to the patients. Blood glucose concentration is a sensitive marker affected by numerous outer environments such as food intake, exercise, stress and medication.[@b3-tcrm-14-1813] On the contrary, HbA1c concentration in the blood reflects the average blood glucose over the previous 8--12 weeks. The HbA1c level can predict the clinical outcome of microvascular[@b4-tcrm-14-1813],[@b5-tcrm-14-1813] and macrovascular complications[@b6-tcrm-14-1813] as well, and the American Diabetes Association (ADA) recommend that HbA1c should be measured at regular intervals in all patients with diabetes.[@b7-tcrm-14-1813] Thus, many researches on diabetes management are using HbA1c as a surrogate marker for clinical outcomes. There have been numerous efforts to implement pharmaceutical care in diabetic patients to improve disease outcomes. Improved management with the consistent support of multidisciplinary pharmaceutical care services can lead to better control of diabetes and fewer complications.[@b8-tcrm-14-1813] For example, in Medication Therapy Management (MTM), a range of services including education, counseling, and assessing each medication and medication-related problems are provided to patients by clinical pharmacists to optimize and improve therapeutic outcomes in the USA.[@b9-tcrm-14-1813] Together with hospital-based clinician-monitored programs, pharmacist-led community/hospital-based pharmaceutical care programs can be designed in an effort to achieve better glycemic, metabolic outcome and blood pressure control in this patient group.[@b10-tcrm-14-1813]

A recent meta-analysis[@b11-tcrm-14-1813] and a systematic review[@b12-tcrm-14-1813] of pharmacist for blood pressure and cardiovascular diseases showed that the implementation of a pharmacist care (PC) model provided improvement in outcomes. The systematic analysis and meta-analysis of PC for diabetic patients showed positive impact on HbA1c outcomes.[@b13-tcrm-14-1813]--[@b15-tcrm-14-1813] However, recent studies reported no significantly different clinical parameters between the PC group and usual care (UC) group,[@b16-tcrm-14-1813]--[@b18-tcrm-14-1813] rendering the need to reevaluate PC. Moreover, they did not present the effectiveness of PC in LMIc apart from high-income countries (HIc). Since the 2016 report of WHO revealed a considerable increase in the number of diabetic patients in LMIc, thus we aimed to evaluate whether the PC service model in HIc and LMIc could improve the clinical outcomes of diabetic patients by performing a meta-analysis including the up-to-date studies.

Methods
=======

Search strategy
---------------

A systematic review protocol conforming to the Effective Practice and Organization of Care (EPOC) guideline was developed and prepared following the PRISMA recommendations.[@b19-tcrm-14-1813] Electronic databases of PubMed, Embase, and ProQuest Dissertations Unlimited Published Literature database were searched by using the following keywords: "diabetes", "diabetes mellitus", "type one diabetes", "type two diabetes", "diabetes type 1", "diabetes type 2", "community pharmacy", "community pharmacies", "community pharmacist", "community pharmacists", "pharmacy", "pharmacist", "hospital pharmacy", "hospital pharmacist", "hospital pharmacists", "pharmacy services", "pharmacist intervention", "pharmaceutical care", "pharmac\*". A manual review was performed to search for unindexed articles in the *Journal of Research in Medical Sciences*, *Journal of American Pharmacists Association* and reference lists of related articles.

Inclusion and exclusion criteria
--------------------------------

The literature search was performed to include studies published up to July 27, 2017, by two independent reviewers. Any disagreement was resolved by discussion among the two reviewers and a third researcher. The inclusion criteria for full-text review were as follows: 1) randomized controlled trial (RCT); 2) confirmed adult diabetic patients (type 1 or type 2); 3) pharmaceutical care intervention by clinical pharmacist or/and multidisciplinary team (PC includes working in cooperation with the patient and other health care providers to assess, monitor, initiate, and modify medication use and to provide education service to health care professionals as well as to the patients); and 4) each article should have reported HbA1c or fasting blood glucose (FBG) level at baseline and end of study or the mean change in these values.

The exclusion criteria were as follows: non-English language, editorials, commentaries, narrative reviews, clinical practice guidelines, conference abstracts, and literature not in peer-reviewed journals. The same reviewers independently evaluated the full text of all identified studies in the first stage of screening and resolved any disagreements.

Outcome assessment
------------------

HbA1c concentration in the blood reflects the average blood glucose over the previous 8--12 weeks. The HbA1c level can predict the clinical outcome of microvascular[@b4-tcrm-14-1813],[@b5-tcrm-14-1813] and macrovascular complications[@b6-tcrm-14-1813] as well, and ADA recommend HbA1c to be measured at regular intervals in all patients with diabetes.[@b7-tcrm-14-1813] Thus, HbA1c has been utilized as an additional stable criterion for assessing glucose control. In this aspect, we chose the difference of HbA1c change and the proportion of patients achieving target HbA1c level (\<7%) between two groups as the main outcome measure.

Data extraction
---------------

The following information was extracted from the full text of included studies by two independent researchers: first author, year of publication, study type, country of study site, disease type of patients, age, service providers, intervention type, and laboratory data pertaining to HbA1c and the number of patients achieving HbA1c goal. The income levels were searched to pool outcomes by income level using the data from the World Bank Group.[@b20-tcrm-14-1813] The duration of intervention was stratified and designated as 1 (\<6 months), 2 (≥6 and \<12 months), and 3 (≥12 months).

Quality score assessment
------------------------

The quality of individual study was assessed by two independent reviewers using the EPOC risk of bias tool. This risk of bias tool is used when the clinical trials involve patient care, educational intervention, patient performance measure, health care quality measure.[@b21-tcrm-14-1813] The standard risk of bias tool includes assessment of domains such as allocation concealment, baseline outcome, baseline characteristics, blinding, and selective reporting.

A domain with a low risk of bias is indicated by "low" and that with a high risk of bias is indicated by "high". If a particular domain has ambiguity or uncertainty due to lack of information, then it is indicated as "unclear".

Statistical analyses
--------------------

The association between HbA1c levels after PC intervention and clinical outcomes was evaluated quantitatively by meta-analysis. The pooled OR were calculated for the included articles stratified by income status of the countries and duration of follow-up (3--5 months, 6--11 months, and ≥12 months). The primary outcome of this study was to evaluate the association between PC and HbA1c change.

Between-study heterogeneity was assessed by Q-statistic (heterogeneity was considered statistically significant if *P*\<0.1)[@b22-tcrm-14-1813] and quantified by *I*^2^ value. Both fixed- and random-effects models were used to combine the aggregate data determined by the *I*^2^ value. When *I*^2^ was \>50%, the random-effects model was used for analysis. Potential publication bias was assessed using the Egger's linear regression test.[@b23-tcrm-14-1813]

Statistical analyses were performed using Comprehensive Meta-Analysis (ver 3; Biostat, Inc., Engelwood, NJ, USA) and IBM SPSS (ver 21; IBM Corporation, Armonk, NY, USA). All tests were two sided, and *P*\<0.05 was considered as significant unless otherwise specified.

Results
=======

PRISMA flow for study selection
-------------------------------

As shown in [Figure 1](#f1-tcrm-14-1813){ref-type="fig"}, of the 3,794 publications identified, 35 publications were found eligible for meta-analysis.

Among the identified publications, 3,465 articles were excluded as inappropriate by title and abstract review. In all, 82 articles were eligible for full-text review. After excluding studies with no pharmacist intervention (n=2), inadequate information (n=10), non-RCT studies (n=41), and non-adult studies (n=2), 27 articles were finally selected. Upon searching for the reference review, 10 additional articles were found to be eligible for meta-analysis; therefore finally, 37 studies were included in the meta-analysis.

Overall review
--------------

In all, 14 articles were published in the North American region (USA \[n=13\] and Canada \[n=1\]), three in the European region (UK, Spain, and Belgium), eight in Asia (Thailand \[n=3\], Hong Kong, Taiwan, Malaysia, Pakistan, and India), six in the Middle East (Jordan \[n=2\], Iraq, Iran \[n=2\], and UAE), three in Brazil, and three in Australia. Brazil, Iran, Iraq, Malaysia, Pakistan, Thailand, Jordan, UAE, and India were classified as LMIc.[@b20-tcrm-14-1813] The intervention period was stratified as follows: intervention period \<6 months (n=7), between 6 and 12 months (n=10), and ≥12 months (n=12). All the trials were conducted in ambulatory settings, including private clinic, hospital-based clinic, community pharmacies, and nationwide health care system or regional health care system ([Table 1](#t1-tcrm-14-1813){ref-type="table"}).

All 37 studies included 2,961 PC and 2,899 UC patients. The overall period of pharmacist intervention was mean 9.07 months (SD 5.73) ranging from 3 to 32 months. In 27 studies, \>100 diabetic patients were enrolled, and in 15 studies, the follow-up period was ≥12 months. The interventions were given from 2-week to 3-month interval, and several studies did not report the interval. The PC was conducted by pharmacists in 24 studies and MTC in 13 studies. The PC program consisted of information on disease and medications, adherence education, survival skills regarding hypo- and hyperglycemia incidence, and insulin injection skills. The delivery type of education or intervention was face-to-face intervention, telephone counseling, or group appointments, meeting, or education sessions. Adjunctive tools such as booklets, disease or medication information sheets, pillbox, and stickers were provided in many studies ([Table 1](#t1-tcrm-14-1813){ref-type="table"}).

The overall pooled analysis for HbA1c change included 35 articles out of total 37 studies ([Table S1](#SD2-tcrm-14-1813){ref-type="supplementary-material"}). Owing to the high *I*^2^ value (89.380), the random-effects model was used. The result was significant and in favor of pharmacist-led intervention on HbA1c change (standard difference in mean values \[SDM\]: 0.379, 95% CI: 0.208--0.550, *P*=0.001), indicating the positive effect of pharmacist intervention in the improvement of clinical parameters in diabetes patients. The HbA1c level was 37.9% more reduced in the PC group than in the UC group ([Figure 2](#f2-tcrm-14-1813){ref-type="fig"}).

The proportion of patients achieving HbA1c goals was evaluated using eight articles that reported targeted outcomes out of total 37 included studies ([Table S2](#SD3-tcrm-14-1813){ref-type="supplementary-material"}). All the seven studies set the HbA1c target \<7%, and the pooled result for the articles was significant and in favor of pharmacist intervention (OR: 2.48, 95% CI: 1.430--4.299, *P*=0.001). Approximately three times more patients achieved their HbA1c goal in the PC group compared to that in the UC group ([Figure 3](#f3-tcrm-14-1813){ref-type="fig"}).

Group analysis for income status and intervention period
--------------------------------------------------------

The stratified meta-analysis showed that PC was significant in both 20 HIc (SDM: 0.351, 95% CI: 0.207--0.495) and 15 LMIc (SDM: 0.426, 95% CI: 0.071--0.780; [Figure 4A](#f4-tcrm-14-1813){ref-type="fig"}). The analysis for intervention period showed that interventions \<6 months did not affect the clinical parameters of the patient (*P*=0.333). In the second group, 6--12 months of pharmacist intervention showed an improved effect, and the patients exhibited 36.4% more mean HbA1c level changes than the UC group (*P*\<0.001). The longest intervention period of ≥12 months exhibited better effect on HbA1c reduction, with 38.8% more change in levels of HbA1c than the UC group (*P*=0.006; [Figure 4B](#f4-tcrm-14-1813){ref-type="fig"}).

Risk of bias score assessment by EPOC
-------------------------------------

The quality score of each study was graded by EPOC risk of bias tool by two independent researchers. As the selected primary literature had a low risk of bias in the domain of baseline outcome measure and characteristics, the baseline characteristics between two groups were similar. The reporting of results section had little risk either. However, the risks on blinding, allocation concealment, and contamination were high due to the nature of educational intervention studies ([Table S3](#SD4-tcrm-14-1813){ref-type="supplementary-material"}).

Publication bias
----------------

As widely accepted tools for publication bias, funnel plot visualization and Egger's regression method were used to detect publication bias. Overall, the funnel plot and Egger's regression (*P*=0.183) methods did not detect publication bias ([Figure S1](#SD1-tcrm-14-1813){ref-type="supplementary-material"}).

Discussion
==========

In this study, we found a significant association between pharmacist-led pharmaceutical care and clinical diabetes management. This finding is corroborated by previous meta-analysis and systematic analysis for cardiovascular disease patients.[@b11-tcrm-14-1813],[@b12-tcrm-14-1813] Well-trained clinical pharmacists and a medical system utilizing active pharmacist-driven patient care can improve the quality, outcomes, and efficiency of patient management. Because this analysis included 20 studies from HIc and 15 from LMIc, the group analysis by income level showed that PC intervention was helpful in improving clinical outcomes in patients with diabetes in both HIc and LMIc. The positive outcomes observed in LMIc are particularly important considering the recent increase in the number of patients with diabetes and metabolic diseases in LMIc. The rapid spread of Western diet and lifestyle, as well as the improvement of socioeconomic status in LMIc, accelerates the incidence of obesity and chronic metabolic diseases in these countries. However, the introduction of clinical PC, such as MTM or multidisciplinary team care, is relatively rare in LMIc compared to that in HIc. A recent review reported that only 12% of clinical PC service is available for drug monitoring activities in Saudi Arabia.[@b24-tcrm-14-1813] Controlling the glucose levels at a recommended level is a difficult task, and therefore, \<57% of these patients achieved control of blood glucose as measured by HbA1c concentrations.[@b25-tcrm-14-1813]

A meta-analysis by Li et al[@b14-tcrm-14-1813] included 14 RCTs and reported higher mean change in HbA1c (0.68) than that in our study (0.370), and another meta-analysis by Poolsup et al[@b15-tcrm-14-1813] included 22 RCTs and reported the same mean change of 0.68 between PC and UC groups. We tried not to include heterogeneous population and excluded the research on adolescents and gestational diabetes patients. We excluded some studies that reported inadequate information to incorporate into meta-analysis that were included in the previous meta-analyses, which might be the reason of the different result. Furthermore, we included additionally 10 recently published studies conducted in LMIc,[@b26-tcrm-14-1813]--[@b35-tcrm-14-1813] and this factor impacted the different results as well.

Generally, the care itself and the social/individual treatment costs of passive medical service administration are challenging. Therefore, more active and interactive multisec-tor collaboration work is essential to manage complicated diseases such as diabetes. In addition, the length of the intervention period is important in achieving adequate effects on clinical parameter improvement.

Another important finding of this study is that the longer intervention period of \>6 months showed significant impact on the clinical parameters, while the intervention period of \<6 months did not. These factors suggest the need for expanded training in primary care, with at least 6 months of education and intervention, to improve the comprehensiveness and quality of care provided to the growing number of patients with diabetes.

From the aspect of intervention tools, most interventions comprise a face-to-face method between pharmacists and patients, supplemented with leaflets and telephone outreach. The growing information age has enabled the availability of high-technology information and education tool kits. To educate diabetic patients, high-technology investments should be accelerated by country-level funding as suggested by a few studies[@b36-tcrm-14-1813]--[@b38-tcrm-14-1813] in which the participants showed a considerable decrease in the HbA1c level and several technological suggestions were provided. The technologies for health care providers include electronic database identifying and tracking patients and computer software designed for clinical decision support to the providers and telemedicine and telecare services, which currently equipped in HIc widely. Specific tool for patients focuses on the self-management skill improvement by the internet-, telephone- and mobile-based tools. If PC service model incorporates these high technologies into the PC, the care can produce much better clinical outcomes. Since most of the HIc have already adopted or are adopting pharmacist-led pharmaceutical care, the results of this study can encourage the utilization of pharmaceutical care in LMIc. A trend was observed in the following LMIc studies conducted in recent years: Obreli-Neto et al,[@b27-tcrm-14-1813] 2011 (Brazil); Mahwi et al,[@b28-tcrm-14-1813] 2013 (Iraq); Samtia et al,[@b29-tcrm-14-1813] 2013 (Pakistan); Cani et al,[@b31-tcrm-14-1813] 2015 (Brazil); Jahangard-Rafsanjani et al,[@b32-tcrm-14-1813] 2015 (Iran); Wishah et al,[@b30-tcrm-14-1813] 2015 (Jordan); and Lim et al,[@b33-tcrm-14-1813] 2016 (Malaysia), except for Jahangard-Rafsanjani et al,[@b32-tcrm-14-1813] 2015 (Iran) and Wishah et al,[@b30-tcrm-14-1813] 2015 (Jordan), in that all the studies showed promising outcomes for pharmacist-led pharmaceutical care strategy in diabetes care in LMIc. A study evaluating the clinical outcome of blood pressure control reported that after stopping the PC, patient behavior returned to pre-intervention level, meaning consistent PC care is needed to better contribute to patients' clinical outcome.[@b39-tcrm-14-1813]

There are some limitations to our study. The risk of bias evaluated by EPOC guideline showed that some of the included publications lack methodical robust in blinding, allocation concealment, and reporting of contaminations. These factors can be considered in future clinical studies to make the results more reliable. The big heterogeneity of included studies is another limitation of this study. This heterogeneity is not from the clinical factor but is derived from statistical or unexplainable factors, so we adopted the random-effects model into the meta-analysis by using a statistic that indicates the percentage of variance in a meta-analysis that is attributable to study heterogeneity (*I*^2^). This model sets an assumption that the effects being estimated in the different studies are not identical but follow some distribution. Even though the random-effects model confronts some criticism but simulations have proven that this method is relatively robust even under wide range of distributional assumptions, both in estimating heterogeneity[@b40-tcrm-14-1813] and calculating an overall effect size.[@b41-tcrm-14-1813] Thus, by using random-effects model in our analysis, the heterogeneity of included studies has been overcome in our research.

Conclusion
==========

Clinical pharmacists can make a comparative evaluation of medications based on sound knowledge of medications. The multitasking of clinical pharmacists, which includes healthy communication with health care workers and active interaction with patients, can lead to adherence to clinical therapeutic guidelines and medications. Pharmacist-led pharmaceutical care is a robust health care strategy maximizing therapeutic efficacy and improving lifelong care in diabetes patients in both HIc and LMIc.

Supplementary materials
=======================

###### 

Publication bias visualized by funnel plot.

**Abbreviation:** SDM, standard difference in mean values.

###### 

The changes in HbA1C between PC group and UC group

  Study ID                                       Intervention group             Control group    Sample size                     *P*-value                    
  ---------------------------------------------- ------------------------------ ---------------- ------------------------------- ---------------- ----- ----- --------
  Jaber 1996[@b77-tcrm-14-1813]                  11.5±2.9                       9.2±2.1          12.2±3.5                        12.1±3.7         17    22    0.003
  Clifford 2002[@b78-tcrm-14-1813]               8.4±1.4                        8.2±1.5          8.5±1.6                         8.1±1.6          48    25    \>0.05
  Raji 2002[@b79-tcrm-14-1813]                   9.9±1.3                        8±1.4            9.8±1.2                         8.6±1.8          50    56    0.03
  Choe 2005[@b80-tcrm-14-1813]                   10.1±1.8                       8±1.4            10.2±1.7                        9.3±2.1          29    36    0.03
  Clifford 2005[@b81-tcrm-14-1813]               −0.5 (−0.7 to −0.3)                             0 (−0.2 to 0.2)                                  92    88    0.002
  Rothman 2005[@b82-tcrm-14-1813]                0.8 (0--1.7%)                                                                                    112   105   0.05
  Suppapitiporn 2005[@b83-tcrm-14-1813]          8.16±1.44                      7.91±1.27        8.01±1.51                       8.8±1.36         180   180   0.001
  Fornos 2006[@b84-tcrm-14-1813]                 8.4±1.8                        7.9±1.7          7.8±1.7                         8.5±1.9          56    56    0.001
  Scott 2006[@b85-tcrm-14-1813]                  8.8±1.72                       7.08±1.72        8.7±0.7                         8±0.7            64    67    0.012
  Krass 2007[@b86-tcrm-14-1813]                  8.9±1.4                        7.9±1.2          8.3±1.3                         8.0±1.2          125   107   \<0.01
  Phumipamorn 2008[@b87-tcrm-14-1813]            8.7±1.5                        7.9±1.4          8.7±1.6                         8.1±1.9          63    67    0.56
  Al Mazroui 2009[@b88-tcrm-14-1813]             8.5 (8.3--8.7)                 6.9 (6.7--7.1)   8.4 (8.2--8.6)                  8.3 (8.1--8.5)   117   117   0.001
  Edelman 2010[@b66-tcrm-14-1813]                9.2                            8.3              9.2                             8.6              133   106   0.159
                                                 −0.33 (−0.80 to 0.13)                                                                                        
  Farsaei 2010[@b89-tcrm-14-1813]                9.3±1.7                        7.5±1.6          8.9±1.1                         9.0±1.2          87    87    \>0.05
  Jameson 2010[@b90-tcrm-14-1813]                −1.5 (−0.03 to −2.68)                           −0.40 (0.5 to −2.10)                             52    51    0.06
  Cohen 2011[@b91-tcrm-14-1813]                  −0.41 (−0.74 to −0.07)                          −0.20 (−0.61 to 0.21)                            50    49    0.028
  Mehuys 2011[@b92-tcrm-14-1813]                 7.7±1.7                        7.1±1.1          7.3±1.2                         7.2±1            153   135   0.009
  Obreli-Neto 2011[@b68-tcrm-14-1813]            −0.7 (−0.9 to 0.5)                              0.0 (−0.1 to 0.1)                                97    97    0.001
  Simpson 2011[@b93-tcrm-14-1813]                −0.15 (−0.36 to 0.05)                           0.03 (−0.22 to 0.28)                             131   129   \<0.05
  Siriam 2011[@b94-tcrm-14-1813]                 8.44±0.29                      6.73±0.21        9.03±0.46                       8.3±0.16         60    60    0.010
  Ali 2012[@b95-tcrm-14-1813]                    8.2±1.65                       6.6±0.59         8.1±0.97                        7.5±0.64         23    23    0.001
  Chan 2012[@b96-tcrm-14-1813]                   −1.57%+1.50%                                    −0.40%+1.19%                                     51    54    \<0.00
  Jacobs 2012[@b97-tcrm-14-1813]                 9.5±1.1                        7.7±1.3          9.2±1                           8.4±1.6          72    92    0.003
  Jarab 2012[@b69-tcrm-14-1813]                  −0.8 (−1.6 to 0.1)                              0.1 (−0.4 to 0.7)                                77    79    0.019
  Kraemer 2012[@b70-tcrm-14-1813]                7.28                           6.78             7.38                            7.22             36    31    0.0757
                                                 −0.5 (change in mean values)                    −0.16 (change in mean values)                                
  Mahwi 2013[@b71-tcrm-14-1813]                  11.53±1.83                     9.2±2            9.97±2.75                       9.5±2.1          62    61    0.001
  Mourao 2013[@b98-tcrm-14-1813]                 −0.6 (−1.1 to −0.02)                            0.7 (0.2--1.3)                                   50    50    0.001
  Samtia 2013[@b72-tcrm-14-1813]                 8.51±1.62                      7.5±1.26         8.54±1.55                       8.08±1.49        178   170   0.001
  O'Connor 2014[@b99-tcrm-14-1813]               −0.9±1.85                                       −1.08±1.78                                       92    103   0.001
  Cani 2015[@b73-tcrm-14-1813]                   9.78±1.55                      9.21±1.41        9.61±1.38                       9.53±1.68        34    36    0.001
  Jahangard-Rafsanjani 2015[@b74-tcrm-14-1813]   7.6±1.6                        6.6±1.5          7.5±1.9                         7.0±1.7          51    50    0.09
  Wishah 2015[@b75-tcrm-14-1813]                 8.9±1.6                        7.2±0.9          8.2±1.3                         7.9±1.3          52    54    \>0.05
  Chen 2016[@b100-tcrm-14-1813]                  9.22±1.7                       8.39±1.2         8.94±1.5                        9.37±1.5         50    50    0.002
  Lim 2016[@b76-tcrm-14-1813]                    10.11±0.26                     9.21±0.27        9.71±0.34                       9.63±0.29        39    37    0.001

**Abbreviations:** PC, pharmacist care; UC, usual care.

###### 

Proportion of patients achieving HbA1c goal between PC group and UC group

  Study ID                              Goal      Intervention group   Control group         
  ------------------------------------- --------- -------------------- --------------- ----- ----
  Scott 2006[@b85-tcrm-14-1813]         A1C\<7%   64                   24              67    4
  Kirwin 2010[@b101-tcrm-14-1813]       A1C\<7%   150                  65              151   57
  Taveira 2010[@b102-tcrm-14-1813]      A1C\<7%   58                   23              51    11
  Cohen 2011[@b91-tcrm-14-1813]         A1C\<7%   50                   20              49    10
  Mehuys 2011[@b92-tcrm-14-1813]        A1C\<7%   153                  80              135   67
  Obreli-Neto 2011[@b68-tcrm-14-1813]   A1C\<7%   97                   19              97    1
  Chan 2012[@b96-tcrm-14-1813]          A1C\<7%   51                   3               54    0
  Jacobs 2012[@b103-tcrm-14-1813]       A1C\<7%   55                   19              67    14

**Abbreviations:** PC, pharmacist care; UC, usual care.

###### 

Quality check for included studies (randomized controlled studies) by EPOC risk of bias

  Study ID                                Sequence generation   Allocation concealment   Baseline outcome measurements   Baseline characteristics   Incomplete outcome data   Blinding of participants, personnel   Protection against contamination   Selective outcome reporting   Other sources of bias
  --------------------------------------- --------------------- ------------------------ ------------------------------- -------------------------- ------------------------- ------------------------------------- ---------------------------------- ----------------------------- -----------------------
  Jaber 1996[@b77-tcrm-14-1813]           Unclear               Unclear                  Low                             Low                        Low                       Unclear                               Unclear                            Low                           Unclear
  Clifford 2002[@b78-tcrm-14-1813]        Low                   Unclear                  Low                             Low                        Low                       Unclear                               Unclear                            Low                           Unclear
  Raji 2002[@b79-tcrm-14-1813]            Unclear               Unclear                  Low                             Low                        Low                       Unclear                               Unclear                            Low                           Unclear
  Choe 2005[@b80-tcrm-14-1813]            Low                   Unclear                  Low                             Low                        Low                       High                                  Low                                Low                           Unclear
  Clifford 2005[@b81-tcrm-14-1813]        Unclear               Unclear                  Low                             Low                        Low                       Low                                   Low                                Low                           Unclear
  Rothman 2005[@b82-tcrm-14-1813]         Low                   Low                      Low                             Low                        Low                       Unclear                               Low                                Low                           Unclear
  Suppapitiporn 2005[@b83-tcrm-14-1813]   Unclear               Unclear                  Low                             Low                        Low                       Unclear                               Unclear                            Low                           Unclear
  Fornos 2006[@b84-tcrm-14-1813]          Low                   Unclear                  Low                             Low                        Low                       High                                  Low                                Unclear                       Unclear
  Scott 2006[@b85-tcrm-14-1813]           Low                   Unclear                  Low                             Low                        Low                       High                                  Low                                Unclear                       Unclear
  Krass 2007[@b86-tcrm-14-1813]           Unclear               Unclear                  Low                             Low                        Low                       High                                  Low                                Low                           Unclear
  Phumipamorn 2008[@b87-tcrm-14-1813]     Low                   High                     Unclear                         Unclear                    Low                       Unclear                               Low                                Low                           Unclear
  Al Mazroui 2009[@b88-tcrm-14-1813]      Unclear               Unclear                  Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Edelman 2010[@b66-tcrm-14-1813]         Low                   Unclear                  Low                             Low                        Unclear                   High                                  Low                                Low                           Unclear
  Farsaei 2010[@b89-tcrm-14-1813]         Unclear               Unclear                  Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Jameson 2010[@b67-tcrm-14-1813]         Low                   Low                      Low                             Low                        Low                       High                                  Unclear                            Low                           Unclear
  Kirwin 2010[@b101-tcrm-14-1813]         Unclear               Unclear                  High                            Low                        Unclear                   Unclear                               High                               High                          Unclear
  Taveira 2010[@b102-tcrm-14-1813]        Low                   Unclear                  High                            High                       Unclear                   Unclear                               Unclear                            High                          Unclear
  Cohen 2011[@b91-tcrm-14-1813]           Unclear               Unclear                  Low                             Low                        Low                       Unclear                               Low                                Low                           Unclear
  Mehuys 2011[@b92-tcrm-14-1813]          Low                   Unclear                  Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Obreli-Neto 2011[@b68-tcrm-14-1813]     Low                   Unclear                  Low                             Low                        High                      High                                  Unclear                            Low                           Unclear
  Simpson 2011[@b93-tcrm-14-1813]         Low                   Unclear                  Low                             Low                        Unclear                   Low                                   Low                                Low                           Low
  Siriam 2011[@b94-tcrm-14-1813]          Unclear               Unclear                  Low                             Low                        Low                       Low                                   Unclear                            Low                           Unclear
  Ali 2012[@b95-tcrm-14-1813]             Low                   Low                      Low                             Low                        Low                       Unclear                               Low                                Low                           Unclear
  Chan 2012[@b96-tcrm-14-1813]            Low                   Low                      Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Jacobs 2012[@b97-tcrm-14-1813]          Low                   Unclear                  Unclear                         Unclear                    Unclear                   Unclear                               Unclear                            Low                           Unclear
  Jarab 2012[@b69-tcrm-14-1813]           Low                   Unclear                  Low                             Low                        Low                       Unclear                               Unclear                            Low                           Unclear
  Kraemer 2012[@b70-tcrm-14-1813]         Low                   Unclear                  Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Mahwi 2013[@b71-tcrm-14-1813]           Low                   Low                      Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Mourao 2013[@b98-tcrm-14-1813]          Low                   Unclear                  Low                             Low                        Low                       Unclear                               Unclear                            Unclear                       Unclear
  Samtia 2013[@b72-tcrm-14-1813]          Unclear               Unclear                  Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Chung 2014[@b104-tcrm-14-1813]          Unclear               Unclear                  Low                             Low                        Low                       Low                                   Low                                Unclear                       Unclear
  O'Connor 2014[@b99-tcrm-14-1813]        Low                   Low                      Low                             Low                        Low                       Low                                   Unclear                            Low                           Unclear
  Cani 2015[@b73-tcrm-14-1813]            Unclear               Unclear                  Low                             Low                        Low                       Low                                   Unclear                            Low                           Unclear
  Jahangard-Rafsanjani                    Low                   Low                      Low                             Low                        Low                       Low                                   Unclear                            Low                           Unclear
  2015[@b74-tcrm-14-1813]                                                                                                                                                                                                                                                            
  Wishah 2015[@b75-tcrm-14-1813]          Low                   Low                      Low                             Low                        Low                       Low                                   Unclear                            Low                           Unclear
  Chen 2016[@b100-tcrm-14-1813]           Low                   Low                      Low                             Low                        Unclear                   Unclear                               Unclear                            Low                           Unclear
  Lim 2016[@b76-tcrm-14-1813]             Unclear               Unclear                  Low                             Low                        Low                       Low                                   Unclear                            Low                           Unclear

**Abbreviation:** EPOC, Effective Practice and Organization of Care.
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![PRISMA flow diagram of selected publications in systematic review and meta-analysis.\
**Abbreviation:** RCT, randomized controlled trial.](tcrm-14-1813Fig1){#f1-tcrm-14-1813}

![The overall comparison of PC and UC on the improvement of HbA1C level changes.\
**Abbreviations:** PC, pharmacist care; UC, usual care; SDM, standard difference in mean values.](tcrm-14-1813Fig2){#f2-tcrm-14-1813}

![Meta-analysis of proportion of patients achieving target HbA1c levels between the PC and UC groups.\
**Abbreviations:** PC, pharmacist care; UC, usual care.](tcrm-14-1813Fig3){#f3-tcrm-14-1813}

###### 

Effect of PC and UC in the improvement of HbA1C levels stratified by income level (**A**) and intervention period (**B**).

**Abbreviations:** PC, pharmacist care; UC, usual care; SDM, standard difference in mean values.
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###### 

Characteristics of randomized controlled studies included in the final analysis

  Study ID                                        Country     Patients     PC/UC (n)   Setting                                                                            Care initiative   Intervention type                                                                                                                                                                                               Duration (months)   Clinical outcomes
  ----------------------------------------------- ----------- ------------ ----------- ---------------------------------------------------------------------------------- ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- -------------------
  Jaber 1996[@b42-tcrm-14-1813]                   USA         T2DM         17/22       University- affiliated internal medicine outpatient clinic                         Pharmacist        Dosage evaluation, patient education, training on hyper and hypoglycemia, medication counseling, dietary regulation and exercise plan, and self-monitoring of blood glucose                                     4                   HbA1c, FBG
  Clifford 2002[@b43-tcrm-14-1813]                Australia   T1DM, T2DM   48/25       Hospital                                                                           MTC               Education and a brochure on risk factors, point-of-care cholesterol measurement, referral to their physician, and drug monitoring                                                                               6                   HbA1c
  Raji 2002[@b44-tcrm-14-1813]                    USA         T1DM, T2DM   50/56       Veterans health care system                                                        MTC               3.5 day-structured curriculum, disease education, group discussion, lifestyle management by direct counseling or telephone intervention, and newsletter provided                                                12                  HbA1c
  Choe 2005[@b45-tcrm-14-1813]                    USA         T2DM         29/36       University- affiliated primary care clinic                                         Pharmacist        Medication review and reconciliation, telephone intervention, lifestyle management, and self-monitoring blood glucose                                                                                           12                  HbA1c
  Clifford 2005[@b46-tcrm-14-1813]                Australia   T2DM         92/88       Fremantle Diabetes Study                                                           Pharmacist        Bimonthly newsletter, educational pamphlets, pharmacotherapeutic intervention, diet, exercise, and compliance with home blood glucose monitoring                                                                12                  HbA1c
  Rothman 2005[@b47-tcrm-14-1813]                 USA         T2DM         112/105     University of North Carolina General Internal Medicine Practice                    Pharmacist        Intensive education and counseling, medication management, and applying evidence-based treatment algorithms                                                                                                     12                  HbA1c
  Suppapitiporn 2005[@b48-tcrm-14-1813]           Thailand    T2DM         180/180     Hospital                                                                           Pharmacist        Patient counseling, drug education, special medication container, and booklet provided                                                                                                                          6                   HbA1c, FBG
  Fornos 2006[@b49-tcrm-14-1813]                  Spain       T2DM         56/56       14 community pharmacies                                                            Pharmacist        Pharmacotherapy follow-up program, adherence education, and medication reconciliation                                                                                                                           14                  HbA1c, FBG
  Scott 2006[@b50-tcrm-14-1813]                   USA         T2DM         76/73       Community Health Center                                                            MTC               Group session appointment, medication review, aspirin therapy and influenza vaccination education, lifestyle management, and telephone follow-up                                                                9                   HbA1c, FBG
  Krass 2007[@b51-tcrm-14-1813]                   Australia   T2DM         149/140     Quality care pharmacy program affiliated to 56 pharmacies                          Pharmacist        Review of self-monitoring of blood glucose, disease, medication, and lifestyle education                                                                                                                        6                   HbA1c
  Phumipamorn 2008[@b52-tcrm-14-1813]             Thailand    T1DM, T2DM   67/68       30-bed community hospital                                                          Pharmacist        Medication adherence, lifestyle management, and leaflet provided                                                                                                                                                10                  HbA1c
  Al Mazroui 2008[@b53-tcrm-14-1813]              UAE         T2DM         117/117     Military hospital                                                                  MTC               Drug education, lifestyle management, leaflet, and medication reconciliation                                                                                                                                    12                  FBG
  Edelman 2010[@b16-tcrm-14-1813]                 USA         T1DM, T2DM   133/106     Two VA medical centers                                                             MTC               Group medical clinic participation, disease education, disease, and medication review                                                                                                                           12.8                HbA1c
  Farsaei 2011[@b26-tcrm-14-1813]                 Iran        T2DM         87/87       One outpatient clinic                                                              MTC               Education and telephone counseling                                                                                                                                                                              3                   HbA1c, FBG
  Jameson 2010[@b18-tcrm-14-1813]                 USA         T1DM, T2DM   52/51       AHPN                                                                               Pharmacist        Individualized education regarding diabetes self-management (diet, exercise, blood glucose level testing, medications, and insulin), early switching to insulin therapy after failure of two oral medications   12                  HbA1c
  Kirwin 2010[@b54-tcrm-14-1813]                  USA         T1DM, T2DM   150/151     Four medical clinics                                                               MTC               Medication review and treatment recommendation letter to physician                                                                                                                                              10                  HbA1c, LDL
  Taveira 2010[@b55-tcrm-14-1813]                 USA         T2DM         58/51       VA medical center                                                                  MTC               Patients' didactic education and behavioral and pharmacological intervention by pharmacist                                                                                                                      4                   HbA1c
  Cohen 2011[@b56-tcrm-14-1813]                   USA         T2DM         50/49       VA medical center                                                                  MTC               Four once weekly 2-hour sessions of education and behavioral and pharmacologic intervention review                                                                                                              6                   HbA1c
  Mehuys 2011[@b57-tcrm-14-1813]                  Belgium     T2DM         153/135     66 community pharmacies                                                            MTC               Disease education, lifestyle management, medication adherence, and regular checkup reminding                                                                                                                    6                   HbA1c, FBG
  Obreli-Neto 2011[@b27-tcrm-14-1813]             Brazil      T1DM, T2DM   97/97       Public primary health care unit                                                    MTC               Group discussion, drug education, lifestyle management, patients' counseling, and medication reconciliation                                                                                                     36                  HbA1c, FBG
  Simpson 2011[@b58-tcrm-14-1813]                 Canada      T2DM         131/129     Five primary care clinics                                                          Pharmacist        Medication review and implementation of guideline concordant recommendations                                                                                                                                    12                  HbA1c
  Siriam 2011[@b59-tcrm-14-1813]                  India       T2DM         60/60       Multi-specialty tertiary care teaching hospital                                    Pharmacist        Medication counseling, dietary regulation, exercise, and lifestyle modifications                                                                                                                                3                   HbA1c, FBG
  Ali 2012[@b60-tcrm-14-1813]                     UK          T2DM         23/23       Two community pharmacies                                                           Pharmacist        Lifestyle management, medication review, disease education, and medication reconciliation                                                                                                                       12                  HbA1c
  Chan 2012[@b61-tcrm-14-1813]                    Hong Kong   T2DM         51/54       250-bed public convalescent hospital                                               Pharmacist        Disease education, medication adherence, and provided color stickers to identify drugs                                                                                                                          9                   HbA1c, FBG
  Jacobs 2012[@b62-tcrm-14-1813]                  USA         T2DM         72/92       Ambulatory general internal medicine setting                                       Pharmacist        Medication review, physical assessment, patients' counseling, disease education, and lifestyle management                                                                                                       12                  HbA1c
  Jarab 2012[@b35-tcrm-14-1813]                   Jordan      T2DM         85/86       762-bed RMS hospital                                                               Pharmacist        Structured patient education and discussion about type 2 diabetes, risks and types of complications from diabetes, prescribed drug therapy, and proper dosage                                                   6                   HbA1c
  Kraemer 2011[@b5-tcrm-14-1813]                  USA         T1DM, T2DM   36/31       Several employer-based health care plans                                           Pharmacist        Disease education, patients' counseling, and referral to physician                                                                                                                                              12                  HbA1c, FBG
  Mahwi 2013[@b28-tcrm-14-1813]                   Iraq        T2DM         62/61       Diabetic center                                                                    Pharmacist        Drug therapy problems and compliance by pill count and Morisky--Green test for drug adherence                                                                                                                   4                   HbA1c, FBG
  Mourao 2013[@b34-tcrm-14-1813]                  Brazil      T2DM         50/50       Six primary health care units integrated into the Brazilian public health system   Pharmacist        Patient education and/or pharmacotherapy changes                                                                                                                                                                6                   HbA1c
  Samtia 2013[@b29-tcrm-14-1813]                  Pakistan    T2DM         174/168     Diabetes clinics                                                                   Pharmacist        Disease education, drug education, and monitoring                                                                                                                                                               5                   HbA1c, FBG
  O'Connor 2014[@b63-tcrm-14-1813]                USA         T1DM, T2DM   92/103      Kaiser Permanente Health Group                                                     MTC               Protocol-structured telephone call and medication adherence reinforcement method                                                                                                                                6                   HbA1c
  Chung 2014[@b64-tcrm-14-1813]                   Thailand    T2DM         120/121     Major teaching hospital                                                            Pharmacist        Medication review, solving drug-related problem, education on diabetes, hypertension, and hyperlipidemia                                                                                                        12                  HbA1c, FBG
  Cani 2015[@b31-tcrm-14-1813]                    Brazil      T2DM         41/37       Teaching hospital                                                                  Pharmacist        Individualized pharmaceutical care plan                                                                                                                                                                         6                   HbA1c
  Jahangard- Rafsanjani 2015[@b32-tcrm-14-1813]   Iran        T2DM         51/50       Community pharmacy                                                                 Pharmacist        Blood glucose self-monitoring device, special logbook and education pamphlets, and medication reconciliation                                                                                                    5                   HbA1c
  Wishah 2015[@b30-tcrm-14-1813]                  Jordan      T2DM         52/54       University hospital                                                                MTC               Structured patients' education and counseling for disease, medication, and lifestyle modification                                                                                                               6                   HbA1c, FBG
  Chen 2016[@b65-tcrm-14-1813]                    Taiwan      T2DM         50/50       Hospital                                                                           Pharmacist        Assessment of adherence, pillbox, insulin injection technique, and medication regiment appropriateness (medication reconciliation)                                                                              6                   HbA1c
  Lim 2016[@b33-tcrm-14-1813]                     Malaysia    T2DM         39/37       Hospital                                                                           Pharmacist        Booklet for disease and medication information, medication counseling, and education                                                                                                                            32                  HbA1c

**Abbreviations:** PC/UC, pharmacist care/usual care; T2DM, type 2 diabetes mellitus; FBG, fasting blood glucose; T1DM, type 1 diabetes mellitus; MTC, Multidisciplinary Team Care; VA, Veterans Affairs; AHPN, Advantage Health Physician Network; RMS, royal medical services; LDL, low density lipoprotein.
